Skip to content

EBITDA at other companies

Dianthus Therapeutics logo
Dianthus TherapeuticsDNTH
-$46.5M-40.3%
Vor Biopharma logo
Vor BiopharmaVOR
-$35.13M-8.2%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$53.62M+2.4%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$38.9M+11.8%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$34.51M-26.0%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN

Other financials

Income statement

See full
Operating income-$46.1M+19.8%
Net income-$44.1M+18.8%
EPS (diluted)-$0.23+37.8%

Balance sheet

See full
Cash & equivalents$175.2M+80.4%
Total debt$25.4M-10.2%
Total equity$204.5M-16.1%
Total assets$262.9M-13.2%

Cash flow

See full
Operating cash flow-$46.8M+6.5%
CapEx--100%
Free cash flow-$46.8M+6.6%

Valuation

See full
Market cap$868.37M+233%
Enterprise value$718.59M+274%

Returns & leverage

See full
Return on equity-87.6%+42.3pp
Debt / equity0.1×0.0×
Current ratio6.4×-1.6×

Where this comes from

Calculated from Annexon’s reported figures.

$46.1Mebit+
$539.0KDepreciation Depletion & Amortization
=-$45.51M

The official record: Annexon’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Annexon's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Annexon's EBITDA?
Annexon (ANNX) reported EBITDA of -$45.51M in Q1 2026.
How has Annexon's EBITDA changed year-over-year?
Annexon's EBITDA increased by 20.0% year-over-year, from -$56.87M to -$45.51M.
What is the long-term trend for Annexon's EBITDA?
Over 4 years (2021 to 2025), Annexon's EBITDA has grown at a 13.6% compound annual growth rate (CAGR), from -$128.57M to -$214.24M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.